Last reviewed · How we verify
NCT06223763: SUROVA
SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery
trial testing Cytoreductive surgery in Epithelial Ovarian Cancer in 5,000 participants. Status unknown.
1 June 2024
Quick facts
| Lead sponsor | Clinica Universidad de Navarra, Universidad de Navarra |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 5,000 |
| Start date | 1 January 2024 |
| Primary completion | 1 June 2024 |
| Estimated completion | 1 June 2024 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Cytoreductive surgery
- Neoadjuvant chemotherapy — full drug profile →
- Adjuvant chemotherapy — full drug profile →
Conditions studied
- Epithelial Ovarian Cancer — all drugs for Epithelial Ovarian Cancer →
- Fallopian Tube Neoplasms — all drugs for Fallopian Tube Neoplasms →
- Peritoneal Neoplasms — all drugs for Peritoneal Neoplasms →
Sponsor
Clinica Universidad de Navarra, Universidad de Navarra
Who can join
Eligibility, female only, with Epithelial Ovarian Cancer or Fallopian Tube Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian tubes, and peritoneum.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian tubes, and peritoneum (SUROVA trial).
Chiva L, Ordás P, Martin-Calvo N, Aramendia JM, et al · · 2024 · cited 6× · PMID 38479803 · DOI 10.1136/ijgc-2024-005354
Verify or expand the search:
- PubMed search for NCT06223763
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cytoreductive surgery
Trials testing the same drug.
- NCT06783491 — Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Ad · Phase 3 · not yet recruiting
- NCT07177105 — Primary Tumor Resection With Sintilimab and Chemotherapy in Advanced NSCLC · Phase 2 · not yet recruiting
- NCT05375825 — Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive S · Phase 1 · withdrawn
- NCT06292286 — Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer · NA · recruiting
- NCT05431530 — Assessment of Quality of Life After Low Anterior Resection During Cytoreductive Surgery for Advanced Ovarian Cancer · recruiting
Other recruiting trials for Epithelial Ovarian Cancer
Currently open trials in the same condition.
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07480954 — Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) · Phase 1, PHASE2 · recruiting
- NCT07218809 — AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Can · Phase 3 · recruiting
- NCT07495397 — Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targete · NA · recruiting
- NCT06915025 — Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemo · Phase 3 · recruiting
Other Clinica Universidad de Navarra, Universidad de Navarra trials
Trials by the same sponsor.
- NCT07370571 — NO AXILLARY SURGERY IN EARLY BREAST CANCER (OXIGENATE) · not yet recruiting
- NCT07165431 — Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2). · NA · recruiting
- NCT07447440 — Role of Pro-Resolving Lipid Mediators in Obesity-Associated Diseases · recruiting
- NCT07191210 — Co-Designed Comprehensive Transition Programme for First-Line Nurse Managers · NA · not yet recruiting
- NCT07132060 — MRI-guided Dose Intensification Program Locally Advanced Pancreatic Cancer · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06223763 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Clinica Universidad de Navarra, Universidad de Navarra
- Last refreshed: 25 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06223763.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing